Ebanga
Product Images NDC 80673-777

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ebanga (NDC 80673-777). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ridgeback Biotherapeutics, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ebanga 01)

A line graph depicting cumulative incidence of mortality (%) over study day 1 to 58, comparing EBANGA versus Control groups. The y-axis shows cumulative mortality percentage from 0 to 100%, and the x-axis represents days of the study. The EBANGA group is represented by a blue line, showing lower cumulative mortality than the Control group, shown by a red line, which rises more steeply and plateaus around 50% mortality.*

FDA Label Image

Image (Ebanga 02)

The image shows a small, compact square barcode label likely used for product identification. The barcode resembles a two-dimensional matrix code, used for scanning and tracking the pharmaceutical product EBANGA by Ridgeback Biotherapeutics, LP. No other text or imagery is present in the image.*

FDA Label Image

Principal Display Panel (Kit Carton)

Box label for EBANGA (ansuvimab-zykl) injection, 400 mg per vial, for intravenous use. The label indicates the package contains 1 carton with 36 vials of 400 mg each. Ridgeback Biotherapeutics, LP is the manufacturer. The product is a lyophilized powder vial for reconstitution and dilution, labeled for Rx only.*

FDA Label Image

Principal Display Panel (Kit Carton)

The packaging label for EBANGA (ansuvimab-zykl) injection by Ridgeback Biotherapeutics, LP shows 400 mg per vial for intravenous use. The carton contains 4 sets of 36 vials each, with each vial containing 400 mg of lyophilized powder for reconstitution. It is marked Rx only and no preservatives or U.S. standard of potency are included.*

FDA Label Image

Principal Display Panel (Kit Carton)

EBANGA (ansuvimab-zykl) for injection 400 mg per vial for intravenous use. The label shows the product comes in a package containing 8 cartons with each carton having 36 vials of 400 mg. Manufactured by Ridgeback Biotherapeutics, LP. The label includes preparation instructions, storage conditions, and a QR code linking to the website www.ebanga.com.*

FDA Label Image

Principal Display Panel (400 mg Vial Label)

Label for EBANGA (ansuvimab-zykl) for Injection, 400 mg per vial. The label indicates it is for intravenous use and must be reconstituted and diluted prior to administration. It is a single-dose vial with instructions to discard unused portions. Storage conditions are 2°C to 8°C, protected from light, and not to be frozen or shaken. Manufactured by Ridgeback Biotherapeutics, LP, Miami, FL.*

FDA Label Image

Principal Display Panel (400 mg Vial Carton)

EBANGA (ansuvimab-zykl) 400 mg per vial for injection, intended for intravenous use. The package displays the product name, dosage strength, route of administration, and contents of 36 vials. It is labeled for Rx only and manufactured by Ridgeback Biotherapeutics, LP. Additional instructions and storage information are included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.